In brief: Acrux, Meditech, Psivida

By Staff Writers
Tuesday, 03 May, 2005

Melbourne's Acrux (ASX: ACR) has Adam Watkinson as its chief scientific officer. Watkinson is currently manager of drug delivery research and project manager at UK pharmaceutical company ProStrakan .

Meditech Research's (ASX: MTR) Ian Nisbet is to present the company's business plans and product data at the Rodman & Renshaw Global Healthcare Conference in Paris on May 5.

pSivida Limited (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) is to present the interim data from its Phase IIa BrachySil trial in patients with primary liver cancer to the European Society for Therapeutic and Radiation Oncology Conference in Budapest on May 5.

Psivida has reported that both patient cohorts from the Phase IIa trial show the product is safe and effective in prompting tumour regression.The final data is expected to be released in June.

Related News

Scientists search for cystitis pain 'off switch'

By targeting certain pain receptors in the bladder, Australian scientists believe that the...

Australia's first cases of H5 avian influenza confirmed

Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd